RU2597989C2 - Конъюгаты и композиции для иммунотерапии и противоопухолевого лечения - Google Patents

Конъюгаты и композиции для иммунотерапии и противоопухолевого лечения Download PDF

Info

Publication number
RU2597989C2
RU2597989C2 RU2012129208/10A RU2012129208A RU2597989C2 RU 2597989 C2 RU2597989 C2 RU 2597989C2 RU 2012129208/10 A RU2012129208/10 A RU 2012129208/10A RU 2012129208 A RU2012129208 A RU 2012129208A RU 2597989 C2 RU2597989 C2 RU 2597989C2
Authority
RU
Russia
Prior art keywords
functionally equivalent
identity
equivalent variant
polypeptide
fusion protein
Prior art date
Application number
RU2012129208/10A
Other languages
English (en)
Russian (ru)
Other versions
RU2012129208A (ru
Inventor
ЛОПЕС Педро БЕРРАОНДО
Джессика ФЬОРАВАНТИ
ЭЧЕВЕРС Хосе МЕДИНА
БЕРМЕХО Игнасио Хавьер МЕЛЕРО
НЬЕТО Мария дель Кармен ОЧОА
ГАРСИА Франсиско де Асис ПАЛАСОН
Сильвия БУЛЬФОНЕ-ПАУС
Эрвин Ханс ДЕЙТМАН
Original Assignee
Проекто Де Биомедисина Сима С.Л.
Рисерч Сентер Борстель
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ES200931158A external-priority patent/ES2362062B1/es
Application filed by Проекто Де Биомедисина Сима С.Л., Рисерч Сентер Борстель filed Critical Проекто Де Биомедисина Сима С.Л.
Publication of RU2012129208A publication Critical patent/RU2012129208A/ru
Application granted granted Critical
Publication of RU2597989C2 publication Critical patent/RU2597989C2/ru

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5443IL-15
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775Apolipopeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2012129208/10A 2009-12-11 2010-12-10 Конъюгаты и композиции для иммунотерапии и противоопухолевого лечения RU2597989C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ES200931158A ES2362062B1 (es) 2009-12-11 2009-12-11 Nuevos conjugados y composiciones para inmunoterapia y tratamiento anti-tumoral.
ESP200931158 2009-12-11
ES201030813 2010-05-27
ESP201030813 2010-05-27
PCT/ES2010/070818 WO2011070214A2 (es) 2009-12-11 2010-12-10 Conjugados y composiciones para inmunoterapia y tratamiento anti-tumoral

Publications (2)

Publication Number Publication Date
RU2012129208A RU2012129208A (ru) 2014-01-20
RU2597989C2 true RU2597989C2 (ru) 2016-09-20

Family

ID=43927978

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012129208/10A RU2597989C2 (ru) 2009-12-11 2010-12-10 Конъюгаты и композиции для иммунотерапии и противоопухолевого лечения

Country Status (11)

Country Link
US (1) US8771664B2 (enExample)
EP (1) EP2511294B1 (enExample)
JP (1) JP5784626B2 (enExample)
CN (1) CN102753574B (enExample)
AU (1) AU2010329805B2 (enExample)
BR (1) BR112012013868A8 (enExample)
CA (1) CA2783876C (enExample)
ES (1) ES2463016T3 (enExample)
MX (1) MX2012006691A (enExample)
RU (1) RU2597989C2 (enExample)
WO (1) WO2011070214A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2854870C2 (ru) * 2023-02-21 2026-01-21 Ремеджен Ко., Лтд. Агонисты il-15 для лечения рака

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015089217A2 (en) 2013-12-10 2015-06-18 Bionz, Llc Methods of developing selective peptide antagonists
ES2778053T3 (es) 2011-01-18 2020-08-07 Bioniz Llc Composiciones para modular la actividad de la citocina gamma-c
EP2537933A1 (en) * 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
KR102539359B1 (ko) * 2013-04-19 2023-06-02 싸이튠 파마 감소된 혈관 누출 증후군에 대한 사이토카인 유도체 치료
CA2954741C (en) * 2013-10-13 2023-10-03 Nova Southeastern University Identification of a natural killer cell population as potential therapeutic targets for gulf war illness and myalgic encephalomyelitis/chronic fatigue syndrome
EP3094351B9 (en) 2014-01-15 2022-04-13 Kadmon Corporation, LLC Immunomodulatory agents
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
WO2015164107A1 (en) 2014-04-23 2015-10-29 Emory University Compositions of gm-csf and interleukin fusions for immune modulation and uses related thereto
US12577323B2 (en) 2015-06-10 2026-03-17 Emory University Compositions and conjugates comprising an interleukin and polypeptides that specifically bind TGF-beta
CN106317225A (zh) * 2015-06-28 2017-01-11 复旦大学 具有靶向性长效白细胞介素22融合蛋白及其制备方法和用途
EP3359556B1 (en) 2015-10-09 2021-05-26 Bioniz, LLC Modulating gamma - c -cytokine activity
EP3443001B1 (en) 2016-04-11 2025-04-30 Obsidian Therapeutics, Inc. REGULATED BIOCIRCUIT SYSTEMS
US11472856B2 (en) 2016-06-13 2022-10-18 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
KR20240142577A (ko) 2017-04-07 2024-09-30 바이오니즈 테라퓨틱스, 아이엔씨. 감마-c-사이토카인 활성의 안정한 조절자
US11344578B2 (en) 2017-04-19 2022-05-31 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
KR20210032924A (ko) 2017-09-05 2021-03-25 토크 테라퓨틱스, 인코포레이티드 치료용 단백질 조성물 및 그의 제조 및 사용 방법
CA3086040A1 (en) 2017-12-19 2019-06-27 Blaze Bioscience, Inc. Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof
WO2019165121A1 (en) 2018-02-21 2019-08-29 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and uses therof
JP2022530677A (ja) 2019-05-03 2022-06-30 バイオニズ リミテッド ライアビリティー カンパニー 脱毛症および脱毛症関連障害の治療ための、γcサイトカインのシグナル伝達の効果の調節
WO2023064469A1 (en) * 2021-10-13 2023-04-20 Modernatx, Inc. Compositions of mrna-encoded il15 fusion proteins and methods of use thereof
EP4565251A1 (en) * 2022-08-07 2025-06-11 Protean Bio, Inc. Peptides for beta-cell survival and insulin production

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987002061A1 (en) * 1985-10-03 1987-04-09 Biotechnology Research Partners, Ltd. Novel lipoprotein-based drug-delivery systems
US20020156007A1 (en) * 2000-11-10 2002-10-24 Proteopharma Aps Apolipoprotein analogues
WO2008007146A1 (en) * 2006-07-13 2008-01-17 Upperton Limited Process for preparing particles of proteinaceous material
AU2008201887A1 (en) * 2000-11-10 2008-05-22 F. Hoffmann-La Roche Ltd. Apolipoprotein analogues

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4999403A (en) 1988-10-28 1991-03-12 Exxon Chemical Patents Inc. Graft polymers of functionalized ethylene-alpha-olefin copolymer with polypropylene, methods of preparation, and use in polypropylene compositions
US5747024A (en) 1993-03-08 1998-05-05 Immunex Corporation Vaccine adjuvant comprising interleukin-15
EP0814838B1 (en) 1995-03-08 2003-05-14 The Scripps Research Institute Antigen presenting system and activation of t-cells
US6787154B2 (en) 1998-10-20 2004-09-07 Salvatore Albani Artificial antigen presenting cells
EP1718282A4 (en) 2004-01-15 2010-07-14 Sinai School Medicine PROCESS AND COMPOSITIONS FOR IMAGE PRESENTATION
WO2006135436A2 (en) 2004-10-22 2006-12-21 University Of Florida Research Foundation, Inc. Inhibition of gene expression and therapeutic uses thereof
US20060257361A1 (en) 2005-04-12 2006-11-16 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Novel form of interleukin-15, Fc-IL-15, and methods of use
US8242081B2 (en) 2005-12-06 2012-08-14 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
KR100817024B1 (ko) 2006-11-09 2008-03-26 재단법인 목암생명공학연구소 핵산 또는 약물을 간에 특이적으로 전달하는 복합체 및이를 포함하는 약학적 조성물
BRPI0915093A2 (pt) 2008-06-13 2015-10-27 Proyecto Biomedicina Cima Sl conjugados para a administração de compostos biologicamente ativos

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987002061A1 (en) * 1985-10-03 1987-04-09 Biotechnology Research Partners, Ltd. Novel lipoprotein-based drug-delivery systems
US20020156007A1 (en) * 2000-11-10 2002-10-24 Proteopharma Aps Apolipoprotein analogues
AU2008201887A1 (en) * 2000-11-10 2008-05-22 F. Hoffmann-La Roche Ltd. Apolipoprotein analogues
WO2008007146A1 (en) * 2006-07-13 2008-01-17 Upperton Limited Process for preparing particles of proteinaceous material

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DUBOIS SIGRID ET AL., Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8(+)/CD44(high) T cells and its antitumor action, JOURNAL OF IMMUNOLOGY, 2008, v. 180, n. 4, p. 2099-2106. *
ВЕЛЬКОВ В.В., Этот загадочный липопротеин (а), 14.09.2007. найдено в интернет [29.08.2014] по адресу: http://cbio.ru/page/43/id/4906/ *
ВЕЛЬКОВ В.В., Этот загадочный липопротеин (а), 14.09.2007. найдено в интернет [29.08.2014] по адресу: http://cbio.ru/page/43/id/4906/. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2854870C2 (ru) * 2023-02-21 2026-01-21 Ремеджен Ко., Лтд. Агонисты il-15 для лечения рака

Also Published As

Publication number Publication date
EP2511294A2 (en) 2012-10-17
CA2783876C (en) 2018-04-03
BR112012013868A8 (pt) 2017-12-26
US20120244118A1 (en) 2012-09-27
EP2511294B1 (en) 2014-02-26
JP5784626B2 (ja) 2015-09-24
CN102753574A (zh) 2012-10-24
WO2011070214A2 (es) 2011-06-16
RU2012129208A (ru) 2014-01-20
MX2012006691A (es) 2013-02-26
AU2010329805A1 (en) 2012-07-05
WO2011070214A3 (es) 2011-08-04
US8771664B2 (en) 2014-07-08
ES2463016T3 (es) 2014-05-27
CN102753574B (zh) 2015-05-20
WO2011070214A8 (es) 2011-09-29
AU2010329805B2 (en) 2016-07-14
CA2783876A1 (en) 2011-06-16
BR112012013868A2 (pt) 2017-01-10
JP2013513377A (ja) 2013-04-22

Similar Documents

Publication Publication Date Title
US8771664B2 (en) Compositions comprising apolipoprotein A polypeptide and interleukin 15, and methods of treatment using the same
EP3307783B1 (en) Compositions and conjugates comprising an interleukin and polypeptides that specifically bind tgf-beta
ES2315008T3 (es) Composiciones que contienen un agente de union a receptor ox-40 o un acido nucleido que codifica el mismo y procedimientos para potenciar la respuesta inmune especifica de antigeno.
US8202847B2 (en) Mutant human CD80 and compositions for and methods of making and using the same
JP7250790B2 (ja) Il-2ムテインおよびその使用
AU729579B2 (en) Immunotherapy and improved vaccines
AU733719B2 (en) Improved vaccines
AU2012202867A1 (en) Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
US20110076304A1 (en) Adapter molecule for the delivery of adenovirus vectors
WO2018162450A1 (en) New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
EP2374813A1 (en) Use of phenol-soluble modulins for vaccine development
ES2362062A1 (es) Nuevos conjugados y composiciones para inmunoterapia y tratamiento anti-tumoral.

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20201211